Coexpression cluster:C973
From FANTOM5_SSTAR
Full id: C973_acute_granulocyte_CD34_CD133_myelodysplastic_biphenotypic_liver
Phase1 CAGE Peaks
Hg19::chr10:129717770..129717798,+ | p@chr10:129717770..129717798 + |
Hg19::chr14:21387508..21387523,+ | p1@ENST00000555624 |
Hg19::chr14:21423643..21423665,+ | p1@RNASE2 |
Hg19::chr19:827823..827845,+ | p1@AZU1 |
Hg19::chr19:829566..829598,+ | p@chr19:829566..829598 + |
Hg19::chr1:200821566..200821577,+ | p@chr1:200821566..200821577 + |
Hg19::chr1:92952473..92952489,- | p3@GFI1 |
Hg19::chr9:137037139..137037152,- | p@chr9:137037139..137037152 - |
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
No results for this coexpression
Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data
GO ID | GO name | FDR corrected p-value |
---|---|---|
GO:0007610 | behavior | 0.000170668921953427 |
GO:0009605 | response to external stimulus | 0.000856400268727817 |
GO:0042330 | taxis | 0.00156594942771625 |
GO:0006935 | chemotaxis | 0.00156594942771625 |
GO:0007626 | locomotory behavior | 0.00156594942771625 |
GO:0042660 | positive regulation of cell fate specification | 0.00156594942771625 |
GO:0042659 | regulation of cell fate specification | 0.00156594942771625 |
GO:0010453 | regulation of cell fate commitment | 0.00156594942771625 |
GO:0009996 | negative regulation of cell fate specification | 0.00156594942771625 |
GO:0010454 | negative regulation of cell fate commitment | 0.00156594942771625 |
GO:0005764 | lysosome | 0.00156594942771625 |
GO:0000323 | lytic vacuole | 0.00156594942771625 |
GO:0005773 | vacuole | 0.00156594942771625 |
GO:0042222 | interleukin-1 biosynthetic process | 0.00156594942771625 |
GO:0050720 | interleukin-1 beta biosynthetic process | 0.00156594942771625 |
GO:0050725 | positive regulation of interleukin-1 beta biosynthetic process | 0.00156594942771625 |
GO:0032603 | fractalkine production | 0.00156594942771625 |
GO:0050752 | regulation of fractalkine biosynthetic process | 0.00156594942771625 |
GO:0045360 | regulation of interleukin-1 biosynthetic process | 0.00156594942771625 |
GO:0050829 | defense response to Gram-negative bacterium | 0.00156594942771625 |
GO:0001774 | microglial cell activation | 0.00156594942771625 |
GO:0050756 | fractalkine metabolic process | 0.00156594942771625 |
GO:0042582 | azurophil granule | 0.00156594942771625 |
GO:0050722 | regulation of interleukin-1 beta biosynthetic process | 0.00156594942771625 |
GO:0050751 | fractalkine biosynthetic process | 0.00156594942771625 |
GO:0042117 | monocyte activation | 0.00156594942771625 |
GO:0045362 | positive regulation of interleukin-1 biosynthetic process | 0.00156594942771625 |
GO:0000083 | G1/S-specific transcription in mitotic cell cycle | 0.00156594942771625 |
GO:0005766 | primary lysosome | 0.00156594942771625 |
GO:0050754 | positive regulation of fractalkine biosynthetic process | 0.00156594942771625 |
GO:0043114 | regulation of vascular permeability | 0.00227308547991789 |
GO:0015643 | toxin binding | 0.00276327747248584 |
GO:0048246 | macrophage chemotaxis | 0.00276327747248584 |
GO:0045123 | cellular extravasation | 0.00276327747248584 |
GO:0008347 | glial cell migration | 0.00309041672193129 |
GO:0045348 | positive regulation of MHC class II biosynthetic process | 0.00309041672193129 |
GO:0032611 | interleukin-1 beta production | 0.00309041672193129 |
GO:0042535 | positive regulation of tumor necrosis factor biosynthetic process | 0.00309041672193129 |
GO:0045342 | MHC class II biosynthetic process | 0.00327718265173903 |
GO:0045346 | regulation of MHC class II biosynthetic process | 0.00327718265173903 |
GO:0007638 | mechanosensory behavior | 0.00327718265173903 |
GO:0045080 | positive regulation of chemokine biosynthetic process | 0.00327718265173903 |
GO:0032612 | interleukin-1 production | 0.00327718265173903 |
GO:0042534 | regulation of tumor necrosis factor biosynthetic process | 0.0040843639790859 |
GO:0042533 | tumor necrosis factor biosynthetic process | 0.0040843639790859 |
GO:0050930 | induction of positive chemotaxis | 0.0040843639790859 |
GO:0050766 | positive regulation of phagocytosis | 0.00415297302491087 |
GO:0042116 | macrophage activation | 0.00415297302491087 |
GO:0045073 | regulation of chemokine biosynthetic process | 0.00415297302491087 |
GO:0050926 | regulation of positive chemotaxis | 0.00415297302491087 |
GO:0032602 | chemokine production | 0.00415297302491087 |
GO:0050764 | regulation of phagocytosis | 0.00415297302491087 |
GO:0050755 | chemokine metabolic process | 0.00415297302491087 |
GO:0050927 | positive regulation of positive chemotaxis | 0.00415297302491087 |
GO:0050918 | positive chemotaxis | 0.00415297302491087 |
GO:0042033 | chemokine biosynthetic process | 0.00415297302491087 |
GO:0042221 | response to chemical stimulus | 0.00415297302491087 |
GO:0050921 | positive regulation of chemotaxis | 0.00445367597835105 |
GO:0050920 | regulation of chemotaxis | 0.00469646549209633 |
GO:0042491 | auditory receptor cell differentiation | 0.00469646549209633 |
GO:0032640 | tumor necrosis factor production | 0.00500428311171623 |
GO:0042490 | mechanoreceptor differentiation | 0.00541852004735126 |
GO:0001708 | cell fate specification | 0.00541852004735126 |
GO:0060113 | inner ear receptor cell differentiation | 0.00541852004735126 |
GO:0045785 | positive regulation of cell adhesion | 0.00541852004735126 |
GO:0009612 | response to mechanical stimulus | 0.00604758798271926 |
GO:0045807 | positive regulation of endocytosis | 0.00630757067606722 |
GO:0004522 | pancreatic ribonuclease activity | 0.00782490789235098 |
GO:0030595 | leukocyte chemotaxis | 0.00782490789235098 |
GO:0048522 | positive regulation of cellular process | 0.00880198465200129 |
GO:0002274 | myeloid leukocyte activation | 0.00880198465200129 |
GO:0042472 | inner ear morphogenesis | 0.00880198465200129 |
GO:0016892 | endoribonuclease activity, producing 3'-phosphomonoesters | 0.00900267811959809 |
GO:0016894 | endonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 3'-phosphomonoesters | 0.00951481855163653 |
GO:0042471 | ear morphogenesis | 0.00957296098955781 |
GO:0050900 | leukocyte migration | 0.00957296098955781 |
GO:0048518 | positive regulation of biological process | 0.00990815612220235 |
GO:0030100 | regulation of endocytosis | 0.0100997738254567 |
GO:0000082 | G1/S transition of mitotic cell cycle | 0.0100997738254567 |
GO:0042063 | gliogenesis | 0.0104899480711891 |
GO:0030141 | secretory granule | 0.0104899480711891 |
GO:0048523 | negative regulation of cellular process | 0.0104899480711891 |
GO:0007205 | protein kinase C activation | 0.0104899480711891 |
GO:0051050 | positive regulation of transport | 0.0104899480711891 |
GO:0048839 | inner ear development | 0.0104899480711891 |
GO:0048519 | negative regulation of biological process | 0.0109312917185369 |
GO:0042108 | positive regulation of cytokine biosynthetic process | 0.0109312917185369 |
GO:0006909 | phagocytosis | 0.0109312917185369 |
GO:0043583 | ear development | 0.0110717633364782 |
GO:0003018 | vascular process in circulatory system | 0.0112090980154521 |
GO:0006401 | RNA catabolic process | 0.0118583097527806 |
GO:0045597 | positive regulation of cell differentiation | 0.0119840494268425 |
GO:0045727 | positive regulation of translation | 0.0133662548911064 |
GO:0042035 | regulation of cytokine biosynthetic process | 0.0148099953883953 |
GO:0031328 | positive regulation of cellular biosynthetic process | 0.0148099953883953 |
GO:0045596 | negative regulation of cell differentiation | 0.0158746968744691 |
GO:0030155 | regulation of cell adhesion | 0.0159416713843611 |
GO:0042089 | cytokine biosynthetic process | 0.0159416713843611 |
GO:0042107 | cytokine metabolic process | 0.0159416713843611 |
GO:0051094 | positive regulation of developmental process | 0.0159416713843611 |
GO:0009891 | positive regulation of biosynthetic process | 0.0160878208787198 |
GO:0032147 | activation of protein kinase activity | 0.0160878208787198 |
GO:0045165 | cell fate commitment | 0.0161587471360076 |
GO:0004521 | endoribonuclease activity | 0.0162282961567073 |
GO:0048731 | system development | 0.0164203155052355 |
GO:0008201 | heparin binding | 0.0168046828430292 |
GO:0051093 | negative regulation of developmental process | 0.0168661806243705 |
GO:0051329 | interphase of mitotic cell cycle | 0.0182725799938739 |
GO:0051247 | positive regulation of protein metabolic process | 0.0182725799938739 |
GO:0007423 | sensory organ development | 0.0183189431602503 |
GO:0007200 | G-protein signaling, coupled to IP3 second messenger (phospholipase C activating) | 0.0185749969893607 |
GO:0051325 | interphase | 0.0188264291644334 |
GO:0048598 | embryonic morphogenesis | 0.0189890375418583 |
GO:0048869 | cellular developmental process | 0.0189890375418583 |
GO:0030154 | cell differentiation | 0.0189890375418583 |
GO:0042742 | defense response to bacterium | 0.0191842623325334 |
GO:0004540 | ribonuclease activity | 0.020018412964898 |
GO:0009617 | response to bacterium | 0.0210359718380921 |
GO:0005539 | glycosaminoglycan binding | 0.0214634223031036 |
GO:0051049 | regulation of transport | 0.0214634223031036 |
GO:0001816 | cytokine production | 0.0218646338971738 |
GO:0048856 | anatomical structure development | 0.0218780868660204 |
GO:0030247 | polysaccharide binding | 0.0220781977342848 |
GO:0001871 | pattern binding | 0.0239691140554861 |
GO:0048015 | phosphoinositide-mediated signaling | 0.0241503841239292 |
GO:0045860 | positive regulation of protein kinase activity | 0.0261781708991172 |
GO:0033674 | positive regulation of kinase activity | 0.0263150892349328 |
GO:0045595 | regulation of cell differentiation | 0.0263150892349328 |
GO:0051347 | positive regulation of transferase activity | 0.0266527202851605 |
GO:0007275 | multicellular organismal development | 0.0268340692406326 |
GO:0004519 | endonuclease activity | 0.0269568012619041 |
GO:0008015 | blood circulation | 0.0281265077720594 |
GO:0003013 | circulatory system process | 0.0281265077720594 |
GO:0009628 | response to abiotic stimulus | 0.0287847587402314 |
GO:0006916 | anti-apoptosis | 0.0294330029785452 |
GO:0003823 | antigen binding | 0.0304133414117029 |
GO:0045321 | leukocyte activation | 0.0307003479160626 |
GO:0006417 | regulation of translation | 0.0311514931079144 |
GO:0010324 | membrane invagination | 0.0326221341500384 |
GO:0006897 | endocytosis | 0.0326221341500384 |
GO:0031326 | regulation of cellular biosynthetic process | 0.0326221341500384 |
GO:0043231 | intracellular membrane-bound organelle | 0.0326221341500384 |
GO:0043227 | membrane-bound organelle | 0.0326221341500384 |
GO:0051707 | response to other organism | 0.033401276685319 |
GO:0001775 | cell activation | 0.0336510168235666 |
GO:0009889 | regulation of biosynthetic process | 0.0346915974216573 |
GO:0043066 | negative regulation of apoptosis | 0.036032784237899 |
GO:0043069 | negative regulation of programmed cell death | 0.0362590966960609 |
GO:0016477 | cell migration | 0.0363718945290016 |
GO:0009790 | embryonic development | 0.0363718945290016 |
GO:0050793 | regulation of developmental process | 0.0363718945290016 |
GO:0045859 | regulation of protein kinase activity | 0.0363718945290016 |
GO:0043549 | regulation of kinase activity | 0.0368910510366623 |
GO:0004518 | nuclease activity | 0.0371619311005411 |
GO:0051338 | regulation of transferase activity | 0.0371619311005411 |
GO:0043085 | positive regulation of catalytic activity | 0.038258949687505 |
GO:0022008 | neurogenesis | 0.0388993562932272 |
GO:0019932 | second-messenger-mediated signaling | 0.0395313438068861 |
GO:0003702 | RNA polymerase II transcription factor activity | 0.0408817939762674 |
GO:0016044 | membrane organization and biogenesis | 0.0413482492717847 |
GO:0009607 | response to biotic stimulus | 0.0418086971382871 |
GO:0006954 | inflammatory response | 0.0418356961900068 |
GO:0032502 | developmental process | 0.0443893580854093 |
GO:0000278 | mitotic cell cycle | 0.0462481083833369 |
GO:0051704 | multi-organism process | 0.0466623480129664 |
GO:0004252 | serine-type endopeptidase activity | 0.0466623480129664 |
GO:0016023 | cytoplasmic membrane-bound vesicle | 0.0483129848461117 |
GO:0031988 | membrane-bound vesicle | 0.048710221809748 |
GO:0009887 | organ morphogenesis | 0.0493156047145424 |
GO:0043229 | intracellular organelle | 0.0493156047145424 |
GO:0043226 | organelle | 0.0493156047145424 |
GO:0031325 | positive regulation of cellular metabolic process | 0.0493156047145424 |
GO:0022403 | cell cycle phase | 0.0495620072767533 |
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>
Ontology term | p-value | n |
---|---|---|
myeloid cell | 6.91e-22 | 108 |
common myeloid progenitor | 6.91e-22 | 108 |
hematopoietic stem cell | 1.35e-15 | 168 |
angioblastic mesenchymal cell | 1.35e-15 | 168 |
hematopoietic cell | 2.31e-14 | 177 |
hematopoietic oligopotent progenitor cell | 4.00e-12 | 161 |
hematopoietic multipotent progenitor cell | 4.00e-12 | 161 |
monopoietic cell | 1.03e-11 | 59 |
monocyte | 1.03e-11 | 59 |
monoblast | 1.03e-11 | 59 |
promonocyte | 1.03e-11 | 59 |
macrophage dendritic cell progenitor | 3.33e-11 | 61 |
single nucleate cell | 2.41e-10 | 3 |
mononuclear cell | 2.41e-10 | 3 |
myeloid leukocyte | 3.61e-10 | 72 |
myeloid lineage restricted progenitor cell | 4.57e-10 | 66 |
granulocyte monocyte progenitor cell | 7.36e-10 | 67 |
defensive cell | 1.96e-08 | 48 |
phagocyte | 1.96e-08 | 48 |
classical monocyte | 2.05e-08 | 42 |
CD14-positive, CD16-negative classical monocyte | 2.05e-08 | 42 |
Ontology term | p-value | n |
---|---|---|
hematopoietic system | 1.24e-15 | 98 |
blood island | 1.24e-15 | 98 |
hemolymphoid system | 1.34e-13 | 108 |
bone element | 1.33e-09 | 82 |
bone marrow | 1.75e-09 | 76 |
immune system | 5.86e-09 | 93 |
skeletal element | 2.28e-08 | 90 |
regional part of nervous system | 4.42e-08 | 53 |
regional part of brain | 4.42e-08 | 53 |
neural tube | 1.68e-07 | 56 |
neural rod | 1.68e-07 | 56 |
future spinal cord | 1.68e-07 | 56 |
neural keel | 1.68e-07 | 56 |
blood | 2.94e-07 | 15 |
haemolymphatic fluid | 2.94e-07 | 15 |
organism substance | 2.94e-07 | 15 |
skeletal system | 4.09e-07 | 100 |
brain grey matter | 5.69e-07 | 34 |
gray matter | 5.69e-07 | 34 |
telencephalon | 5.87e-07 | 34 |
regional part of forebrain | 9.58e-07 | 41 |
forebrain | 9.58e-07 | 41 |
anterior neural tube | 9.58e-07 | 41 |
future forebrain | 9.58e-07 | 41 |
Ontology term | p-value | n |
---|---|---|
myeloid leukemia | 1.76e-25 | 31 |
leukemia | 2.24e-19 | 39 |
hematologic cancer | 7.76e-14 | 51 |
immune system cancer | 7.76e-14 | 51 |
Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
Motifs | -log10(p-value) |
---|---|
MA0003.1 | 0.393486 |
MA0004.1 | 0.455723 |
MA0006.1 | 0.300178 |
MA0007.1 | 0.437331 |
MA0009.1 | 0.918715 |
MA0014.1 | 0.473479 |
MA0017.1 | 0.337901 |
MA0019.1 | 0.602411 |
MA0024.1 | 0.813542 |
MA0025.1 | 1.05265 |
MA0027.1 | 2.5321 |
MA0028.1 | 0.315574 |
MA0029.1 | 0.832916 |
MA0030.1 | 0.821423 |
MA0031.1 | 0.756713 |
MA0038.1 | 0.557409 |
MA0040.1 | 0.838784 |
MA0041.1 | 1.19384 |
MA0042.1 | 0.442535 |
MA0043.1 | 0.919032 |
MA0046.1 | 0.90778 |
MA0048.1 | 0.316923 |
MA0050.1 | 0.443405 |
MA0051.1 | 0.553205 |
MA0052.1 | 0.842664 |
MA0055.1 | 0.524515 |
MA0056.1 | 0 |
MA0057.1 | 0.632427 |
MA0058.1 | 0.362328 |
MA0059.1 | 0.361075 |
MA0060.1 | 0.190336 |
MA0061.1 | 0.961853 |
MA0063.1 | 0 |
MA0066.1 | 0.557833 |
MA0067.1 | 1.23721 |
MA0068.1 | 0.133123 |
MA0069.1 | 0.903908 |
MA0070.1 | 0.892666 |
MA0071.1 | 0.518907 |
MA0072.1 | 0.888148 |
MA0073.1 | 0.215282 |
MA0074.1 | 0.552456 |
MA0076.1 | 0.377799 |
MA0077.1 | 0.880402 |
MA0078.1 | 0.652193 |
MA0081.1 | 0.361233 |
MA0083.1 | 0.926258 |
MA0084.1 | 1.42483 |
MA0087.1 | 0.885691 |
MA0088.1 | 0.054222 |
MA0089.1 | 0 |
MA0090.1 | 0.391903 |
MA0091.1 | 2.02209 |
MA0092.1 | 1.07975 |
MA0093.1 | 0.303084 |
MA0095.1 | 0 |
MA0098.1 | 0 |
MA0100.1 | 0.571227 |
MA0101.1 | 0.30624 |
MA0103.1 | 0.291333 |
MA0105.1 | 1.47197 |
MA0106.1 | 1.45807 |
MA0107.1 | 0.666147 |
MA0108.2 | 0.753643 |
MA0109.1 | 0 |
MA0111.1 | 0.405141 |
MA0113.1 | 0.614917 |
MA0114.1 | 0.655057 |
MA0115.1 | 1.1606 |
MA0116.1 | 1.94086 |
MA0117.1 | 0.956472 |
MA0119.1 | 1.63558 |
MA0122.1 | 0.982472 |
MA0124.1 | 1.11898 |
MA0125.1 | 1.0347 |
MA0130.1 | 0 |
MA0131.1 | 0.670358 |
MA0132.1 | 0 |
MA0133.1 | 0 |
MA0135.1 | 0.949204 |
MA0136.1 | 0.564434 |
MA0139.1 | 0.155155 |
MA0140.1 | 0.516266 |
MA0141.1 | 0.359385 |
MA0142.1 | 0.724856 |
MA0143.1 | 0.615094 |
MA0144.1 | 0.623945 |
MA0145.1 | 0.480646 |
MA0146.1 | 0.65158 |
MA0147.1 | 0.681318 |
MA0148.1 | 0.480298 |
MA0149.1 | 0.506665 |
MA0062.2 | 0.161302 |
MA0035.2 | 0.515566 |
MA0039.2 | 0.44475 |
MA0138.2 | 0.653421 |
MA0002.2 | 2.2946 |
MA0137.2 | 0.321796 |
MA0104.2 | 1.05746 |
MA0047.2 | 0.586412 |
MA0112.2 | 0.79629 |
MA0065.2 | 0.226158 |
MA0150.1 | 0.386144 |
MA0151.1 | 0 |
MA0152.1 | 0.52279 |
MA0153.1 | 1.01778 |
MA0154.1 | 0.274121 |
MA0155.1 | 0.197713 |
MA0156.1 | 0.865715 |
MA0157.1 | 0.697424 |
MA0158.1 | 0 |
MA0159.1 | 1.96124 |
MA0160.1 | 0.495355 |
MA0161.1 | 0 |
MA0162.1 | 0.378102 |
MA0163.1 | 0.141536 |
MA0164.1 | 0.627336 |
MA0080.2 | 0.303167 |
MA0018.2 | 0.599912 |
MA0099.2 | 0.523145 |
MA0079.2 | 0.13841 |
MA0102.2 | 3.22015 |
MA0258.1 | 0.209744 |
MA0259.1 | 0.25092 |
MA0442.1 | 0 |
ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data
No analysis results for this cluster
Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data
This analysis result is provided for C0 - C305 clusters.